Scientists Replicate Crohn's Disease Fat Phenomenon in Lab Rats

A new Crohn’s disease rat model is giving researchers a clearer way to study the fat changes that surround inflamed intestines. The model drew notice on March 12, 2026

Creeping Fat Gets a Usable Model

Researchers in Catalonia have cleared a significant hurdle in the study of inflammatory bowel disease by successfully replicating a mysterious tissue growth in laboratory rats. Leading teams from the Germans Trias i Pujol Research Institute, known as IGTP, and the Institut de Recerca Biomedica Catalunya Sud worked in tandem to create this new biological framework. Their findings, published in the journal Inflammatory Bowel Diseases, focus on a pathological feature known as creeping fat. Creeping fat involves the abnormal expansion of mesenteric adipose tissue, which physically wraps around sections of the intestine affected by Crohn's disease. Until now, scientists lacked a reliable animal model to observe how this fat behaves or why it targets specific areas of the gut. Creeping fat is a physical hallmark of Crohn's disease, yet it remained an enigma for decades. Surgeons often use the presence of this tissue as a visual guide during operations to identify the exact boundaries of diseased bowel segments. While clinicians recognized its diagnostic utility, the underlying mechanisms driving its growth were difficult to pin down. Scientists previously viewed this fat as a passive bystander or a simple protective cushion. Modern research suggests a far more active and potentially destructive role. This development provides a controlled environment where the interactions between the gut wall and the surrounding fat can be measured with precision. Understanding the pathology of Crohn's requires a look back at the history of the disease itself. Burrill Bernard Crohn and his colleagues first described the condition in 1932, noting the transmural inflammation that penetrates every layer of the intestinal wall, because it gave Crohn's researchers a better way to study tissue outside the bowel wall.

Crohn's Is More Than the Gut Lining

Most existing laboratory models for inflammatory bowel disease focus exclusively on the inner lining of the gut, known as the mucosa. These models typically use chemicals like dextran sulfate sodium to trigger short-term inflammation. Such methods fail to capture the complex relationship between the intestine and the exterior mesenteric fat. The Catalan team addressed the gap with a specialized rat model designed to trigger the fat-wrapping phenomenon seen in human patients. Scientists at IRB CatSud and IGTP found that the fat does not just sit there. Instead, it acts as an immunological organ. It secretes various signaling molecules, called adipokines, which can either dampen or fuel the fire of inflammation. By using the new rat model, investigators can now track how these molecules migrate from the fat into the bowel wall. This specific model replicates the architectural changes seen in humans, including the thickening of the mesentery and the migration of adipocytes toward the inflamed segments. Disease management currently relies heavily on biologics that target the immune system globally. Yet, many patients do not respond to these therapies or lose response over time. Biological models that include creeping fat allow pharmaceutical companies to test drugs that might target the fat-gut axis specifically. If a medication can stop the fat from "creeping," it might prevent the scarring and narrowing of the intestine that often leads to emergency surgery.

The Catalan team overcame this by developing a specialized rat model that specifically triggers the fat-wrapping phenomenon seen in human patients.

The Fat-Gut Axis Needs Attention

Researchers believe that the fat might actually be trying to heal the gut, but the process goes awry, leading to the very complications it seeks to prevent. Fat-gut communication is a two-way street. Inflammation in the intestine sends signals to the mesenteric fat, which then responds by expanding and migrating. The Catalan study highlights how the fat reacts to bacterial translocation, where gut bacteria leak through a weakened intestinal barrier. In the rat model, the fat appears to act as a secondary defense line, attempting to contain these leaking microbes. This approach shifts the focus of Crohn's research from the inside of the tube to the outside environment of the abdominal cavity. Success in creating this model comes after years of frustration in the field of gastroenterology. Many previous attempts to mimic creeping fat in rodents resulted in either too much systemic illness or no fat involvement at all.

The IGTP and IRB CatSud teams refined their protocol to ensure the rats developed a localized, chronic inflammatory response. The consistency is key for long-term studies that look at how the disease progresses over months rather than days. It allows for the observation of fibrosis, the tough scar tissue that makes Crohn's so difficult to treat without surgery. Metabolic factors also play a role in how this fat behaves.

Crohn's disease is often associated with weight loss and malnutrition, yet the fat around the diseased gut grows even when the patient is losing weight elsewhere.

Drug Research Gains a Better Target

The paradox suggests that the growth is not driven by caloric intake but by local inflammatory cues. The rat model provides a way to decouple these metabolic signals. Investigators can now study the fat in lean versus obese subjects to see if underlying metabolic health changes the severity of the creeping fat phenomenon. Collaboration between the two Catalan institutes allowed for a multi-disciplinary approach.

IGTP provided the deep clinical expertise in inflammatory diseases, while IRB CatSud contributed advanced imaging and molecular analysis techniques. Their joint effort addresses a major gap in the medical literature regarding the extra-intestinal manifestations of IBD. Most textbooks still describe Crohn's primarily as a mucosal disease, but this research underscores the need to view it as a systemic disorder involving the entire mesenteric unit. Future clinical trials may soon incorporate findings from this rat model.

By identifying specific proteins produced by the fat in the rats, doctors can look for those same markers in human blood or stool samples. That could lead to a non-invasive way to measure how much creeping fat a patient has without the need for expensive MRI scans or invasive surgery. The ability to monitor this tissue in real-time would revolutionize how gastroenterologists adjust treatment plans for high-risk patients. Precision medicine requires models that reflect the true diversity of human disease.

Crohn's disease presents differently in every patient, with some developing strictures and others developing fistulas.

Medicine Ignored the Tissue Beside the Disease

Scientists replicated the Crohn's disease creeping fat phenomenon in laboratory rats. The model may help researchers study how mesenteric fat interacts with gut inflammation. Understanding the fat-gut axis could support better drug testing and disease monitoring. The work challenges overly narrow models that focus only on the intestinal lining.

Creeping fat is the abnormal expansion of fat around diseased bowel segments in Crohn's disease. A rat model gives researchers a controlled way to study mechanisms and test therapies before clinical trials.

The model matters because it attacks a blind spot. Crohn's research has spent too much time treating the bowel wall as the whole battlefield while the surrounding fat behaves like an active immune organ. If creeping fat helps drive scarring, narrowing or relapse, then therapies that ignore it are incomplete by design.